Monthly
US$200
Billed every month
Furosemide Injection(呋塞米注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Marketing application approved: 1 applicationAccepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders27View records ↓
Under-review filings6View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers57View records ↓
API companies with A status20View records ↓
Chemical-drug catalogue
Loaded records: 27 holders; 14 in the quality-and-efficacy consistency-evaluation category, and 12 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 上海锦帝九州药业（安阳）有限公司 | 上海锦帝九州药业（安阳）有限公司 | 国药准字H20045164 | 2026/03/09 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 江苏润恒制药有限公司 | 江苏润恒制药有限公司 | 国药准字H20263434 | 2026/02/25 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 酒泉大得利制药股份有限公司 | 酒泉大得利制药股份有限公司 | 国药准字H20263144 | 2026/01/20 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南药科院生物医药股份有限公司 | 楚雄和创药业有限责任公司 | 国药准字H20253555 | 2025/03/04 | 2ml：20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林省辉南长龙生化药业股份有限公司 | 吉林省辉南长龙生化药业股份有限公司 | 国药准字H20249770 | 2024/12/25 | 2ml：20mg | Not stated by source | CDE |
| 石家庄四药有限公司 | 石家庄四药有限公司 | 国药准字H13020021 | 2024/12/20 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 石药银湖制药有限公司 | 石药银湖制药有限公司 | 国药准字H14022627 | 2024/12/09 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 石药集团欧意药业有限公司 | 石药集团欧意药业有限公司 | 国药准字H13021034 | 2024/12/05 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 武汉久安药业有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20249587 | 2024/12/01 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉久安药业有限公司 | 四川美大康佳乐药业有限公司 | 国药准字H20249586 | 2024/12/01 | 10ml:100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 遂成药业股份有限公司 | 遂成药业股份有限公司 | 国药准字H41021056 | 2024/11/12 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20244406 | 2024/07/09 | 10ml:100mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 中国大冢制药有限公司 | 中国大冢制药有限公司 | 国药准字H20243838 | 2024/05/28 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽长江药业有限公司 | 安徽长江药业有限公司 | 国药准字H34021984 | 2024/01/04 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 吉林振澳制药有限公司 | 吉林振澳制药有限公司 | 国药准字H20233896 | 2023/06/30 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特药业股份有限公司 | 海南倍特药业有限公司 | 国药准字H20237064 | 2023/06/14 | 10ml：100mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 成都倍特药业股份有限公司 | 海南倍特药业有限公司 | 国药准字H32021527 | 2023/06/14 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 嘉实（湖南）医药科技有限公司 | 湖南五洲通药业股份有限公司 | 国药准字H20233276 | 2023/03/15 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州瑞尔医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20233104 | 2023/01/31 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州民生药业股份有限公司 | 杭州民生药业股份有限公司 | 国药准字H20233048 | 2023/01/10 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山东北大高科华泰制药有限公司 | 扬州中宝药业股份有限公司 | 国药准字H20223898 | 2022/11/30 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北天圣药业有限公司 | 湖北天圣药业有限公司 | 国药准字H42020417 | 2022/11/11 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 上海禾丰制药有限公司 | 上海禾丰制药有限公司 | 国药准字H31021063 | 2022/10/09 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 山东新华制药股份有限公司 | 山东新华制药股份有限公司 | 国药准字H37020293 | 2022/10/08 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 上海朝晖药业有限公司 | 上海朝晖药业有限公司 | 国药准字H31021075 | 2022/03/09 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 河南润弘制药股份有限公司 | 河南润弘制药股份有限公司 | 国药准字H41020310 | 2022/02/22 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 天津金耀药业有限公司 | 天津金耀药业有限公司 | 国药准字H12020527 | 2022/01/12 | 2ml:20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 天津金耀集团湖北天药药业股份有限公司 | 天津金耀集团湖北天药药业股份有限公司 | 国药准字H42020034 | 2021/12/21 | 2ml：20mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 南京泽恒医药技术开发有限公司 | 亚邦医药股份有限公司 | 国药准字H20213920 | 2021/12/08 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 仁合益康集团有限公司 | 河北仁合益康药业有限公司 | 国药准字H20244405 | 2024/07/09 | 2ml:20mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 57 distinct approval numbers and 55 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广东南国药业有限公司 | 国药准字H44022506 | 2ml:20mg | Category A (甲) | XC03CAF056B002010100315 | NHSA |
| 广东新峰药业股份有限公司 | 国药准字H44022003 | 2ml:20mg | Category A (甲) | XC03CAF056B002010100326 | NHSA |
| 上海朝晖药业有限公司 | 国药准字H31021075 | 2ml:20mg | Category A (甲) | XC03CAF056B002010100665 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021063 | 2ml:20mg | Category A (甲) | XC03CAF056B002010100673 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H12020527 | 2ml:20mg | Category A (甲) | XC03CAF056B002010100874 | NHSA |
| 中国大冢制药有限公司 | 国药准字H20243838 | 2ml:20mg | Category A (甲) | XC03CAF056B002010100967 | NHSA |
| 西南药业股份有限公司 | 国药准字H50020101 | 2ml:20mg | Category A (甲) | XC03CAF056B002010100978 | NHSA |
| 江苏悦兴药业有限公司 | 国药准字H32020064 | 2ml:20mg | Category A (甲) | XC03CAF056B002010101631 | NHSA |
| 海南倍特药业有限公司 | 国药准字H32021527 | 2ml:20mg | Category A (甲) | XC03CAF056B002010101708 | NHSA |
| 江苏朗欧药业有限公司 | 国药准字H32021067 | 2ml:20mg | Category A (甲) | XC03CAF056B002010101723 | NHSA |
| 武汉福星生物药业有限公司 | 国药准字H42023005 | 2ml:20mg | Category A (甲) | XC03CAF056B002010101799 | NHSA |
| 湖北天圣药业有限公司 | 国药准字H42020417 | 2ml:20mg | Category A (甲) | XC03CAF056B002010101842 | NHSA |
| 湖北津药药业股份有限公司 | 国药准字H42020034 | 2ml:20mg | Category A (甲) | XC03CAF056B002010101866 | NHSA |
| 武汉久安药业有限公司 | 国药准字H20249587 | 2ml:20mg | Category A (甲) | XC03CAF056B002010101949 | NHSA |
| 宜昌人福药业有限责任公司 | 国药准字H42022075 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102000 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20237064 | 10ml:100mg | Category A (甲) | XC03CAF056B002010102013 | NHSA |
| 成都第一制药有限公司 | 国药准字H51023139 | 2ml：20mg | Category A (甲) | XC03CAF056B002010102065 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H51023158 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102087 | NHSA |
| 西安风华药业有限公司 | 国药准字H61021124 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102420 | NHSA |
| 西安迪赛生物药业有限责任公司 | 国药准字H61021139 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102470 | NHSA |
| 河北武罗药业有限公司 | 国药准字H13021427 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102601 | NHSA |
| 石家庄四药有限公司 | 国药准字H13020021 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102677 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H13021034 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102770 | NHSA |
| 山西国润制药有限公司 | 国药准字H14020650 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102839 | NHSA |
| 石药银湖制药有限公司 | 国药准字H14022627 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102954 | NHSA |
| 亚宝药业集团股份有限公司 | 国药准字H20055861 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102987 | NHSA |
| 上海锦帝九州药业(安阳)有限公司 | 国药准字H20045164 | 2ml:20mg | Category A (甲) | XC03CAF056B002010102994 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41021794 | 2ml:20mg | Category A (甲) | XC03CAF056B002010103139 | NHSA |
| 河南润弘制药股份有限公司 | 国药准字H41020310 | 2ml:20mg | Category A (甲) | XC03CAF056B002010103257 | NHSA |
| 长白山制药股份有限公司 | 国药准字H22024699 | 2ml:20mg | Category A (甲) | XC03CAF056B002010103291 | NHSA |
| 中嘉生物科技(湖北省)有限公司 | 国药准字H20053949 | 2ml:20mg | Category A (甲) | XC03CAF056B002010103377 | NHSA |
| 吉林省辉南长龙生化药业股份有限公司 | 国药准字H20249770 | 2ml:20mg | Category A (甲) | XC03CAF056B002010103421 | NHSA |
| 黑龙江省格润药业有限责任公司 | 国药准字H23022350 | 2ml:20mg | Category A (甲) | XC03CAF056B002010103820 | NHSA |
| 山东方明药业集团股份有限公司 | 国药准字H37021056 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104083 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H37020293 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104187 | NHSA |
| 山东益健药业有限公司 | 国药准字H20058876 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104192 | NHSA |
| 山东圣鲁制药有限公司 | 国药准字H37021208 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104207 | NHSA |
| 许昌未来制药有限责任公司 | 国药准字H34020774 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104338 | NHSA |
| 安徽长江药业有限公司 | 国药准字H34021984 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104451 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20233048 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104494 | NHSA |
| 福建南少林药业有限公司 | 国药准字H35020028 | 2ml:20mg | Category A (甲) | XC03CAF056B002010104784 | NHSA |
| 云南白药集团股份有限公司 | 国药准字H53020033 | 2ml:20mg | Category A (甲) | XC03CAF056B002010105607 | NHSA |
| 甘肃兰药药业有限公司 | 国药准字H62020717 | 2ml:20mg | Category A (甲) | XC03CAF056B002010105863 | NHSA |
| 酒泉大得利制药股份有限公司 | 国药准字H20263144 | 2ml:20mg | Category A (甲) | XC03CAF056B002010105888 | NHSA |
| 吉林振澳制药有限公司 | 国药准字H20233896 | 2ml:20mg | Category A (甲) | XC03CAF056B002010109876 | NHSA |
| 海鸿恒隆(海南)生物科技有限公司 | 国药准字H20213920 | 2ml:20mg | Category A (甲) | XC03CAF056B002010110144 | NHSA |
| 西藏珠峰寿高生物药业有限公司 | 国药准字H20223898 | 2ml:20mg | Category A (甲) | XC03CAF056B002010181161 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20244405 | 2ml:20mg | Category A (甲) | XC03CAF056B002010183033 | NHSA |
| 海南金瑞宝医药科技有限公司 | 国药准字H20233276 | 2ml:20mg | Category A (甲) | XC03CAF056B002010183048 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20233104 | 2ml:20mg | Category A (甲) | XC03CAF056B002010183450 | NHSA |
| 云南药科院生物医药股份有限公司 | 国药准字H20253555 | 2ml:20mg | Category A (甲) | XC03CAF056B002010184547 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20263434 | 2ml:20mg | Category A (甲) | XC03CAF056B002010185467 | NHSA |
| 广东南国药业有限公司 | 国药准字H44022506 | 2ml:20mg | Category A (甲) | XC03CAF056B002010200315 | NHSA |
| 广东新峰药业股份有限公司 | 国药准字H44022003 | 2ml:20mg | Category A (甲) | XC03CAF056B002010200326 | NHSA |
| 上海禾丰制药有限公司 | 国药准字H31021063 | 2ml:20mg | Category A (甲) | XC03CAF056B002010200673 | NHSA |
| 西南药业股份有限公司 | 国药准字H50020101 | 2ml:20mg | Category A (甲) | XC03CAF056B002010200978 | NHSA |
| 海南倍特药业有限公司 | 国药准字H32021527 | 2ml:20mg | Category A (甲) | XC03CAF056B002010201708 | NHSA |
| 江苏朗欧药业有限公司 | 国药准字H32021067 | 2ml:20mg | Category A (甲) | XC03CAF056B002010201723 | NHSA |
| 武汉福星生物药业有限公司 | 国药准字H42023005 | 2ml:20mg | Category A (甲) | XC03CAF056B002010201799 | NHSA |
| 湖北津药药业股份有限公司 | 国药准字H42020034 | 2ml:20mg | Category A (甲) | XC03CAF056B002010201866 | NHSA |
| 武汉久安药业有限公司 | 国药准字H20249587 | 2ml:20mg | Category A (甲) | XC03CAF056B002010201949 | NHSA |
| 成都倍特药业股份有限公司 | 国药准字H20237064 | 10ml:100mg | Category A (甲) | XC03CAF056B002010202013 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H51023158 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202087 | NHSA |
| 西安风华药业有限公司 | 国药准字H61021124 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202420 | NHSA |
| 陕西顿斯制药有限公司 | 国药准字H61021680 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202503 | NHSA |
| 河北武罗药业有限公司 | 国药准字H13021427 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202601 | NHSA |
| 石家庄四药有限公司 | 国药准字H13020021 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202677 | NHSA |
| 石药集团欧意药业有限公司 | 国药准字H13021034 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202770 | NHSA |
| 石药银湖制药有限公司 | 国药准字H14022627 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202954 | NHSA |
| 上海锦帝九州药业(安阳)有限公司 | 国药准字H20045164 | 2ml:20mg | Category A (甲) | XC03CAF056B002010202994 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41021794 | 2ml:20mg | Category A (甲) | XC03CAF056B002010203139 | NHSA |
| 河南润弘制药股份有限公司 | 国药准字H41020310 | 2ml:20mg | Category A (甲) | XC03CAF056B002010203257 | NHSA |
| 中嘉生物科技(湖北省)有限公司 | 国药准字H20053949 | 2ml:20mg | Category A (甲) | XC03CAF056B002010203377 | NHSA |
| 吉林省辉南长龙生化药业股份有限公司 | 国药准字H20249770 | 2ml:20mg | Category A (甲) | XC03CAF056B002010203421 | NHSA |
| 山东方明药业集团股份有限公司 | 国药准字H37021056 | 2ml:20mg | Category A (甲) | XC03CAF056B002010204083 | NHSA |
| 山东新华制药股份有限公司 | 国药准字H37020293 | 2ml:20mg | Category A (甲) | XC03CAF056B002010204187 | NHSA |
| 山东益健药业有限公司 | 国药准字H20058876 | 2ml:20mg | Category A (甲) | XC03CAF056B002010204192 | NHSA |
| 许昌未来制药有限责任公司 | 国药准字H34020774 | 2ml:20mg | Category A (甲) | XC03CAF056B002010204338 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20233048 | 2ml:20mg | Category A (甲) | XC03CAF056B002010204494 | NHSA |
| 福建南少林药业有限公司 | 国药准字H35020028 | 2ml:20mg | Category A (甲) | XC03CAF056B002010204784 | NHSA |
| 甘肃兰药药业有限公司 | 国药准字H62020717 | 2ml:20mg | Category A (甲) | XC03CAF056B002010205863 | NHSA |
| 吉林振澳制药有限公司 | 国药准字H20233896 | 2ml:20mg | Category A (甲) | XC03CAF056B002010209876 | NHSA |
| 西藏珠峰寿高生物药业有限公司 | 国药准字H20223898 | 2ml:20mg | Category A (甲) | XC03CAF056B002010281161 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20244405 | 2ml:20mg | Category A (甲) | XC03CAF056B002010283033 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20233104 | 2ml:20mg | Category A (甲) | XC03CAF056B002010283450 | NHSA |
| 云南药科院生物医药股份有限公司 | 国药准字H20253555 | 2ml:20mg | Category A (甲) | XC03CAF056B002010284547 | NHSA |
| 江苏润恒制药有限公司 | 国药准字H20263434 | 2ml:20mg | Category A (甲) | XC03CAF056B002010285467 | NHSA |
| 陕西顿斯制药有限公司 | 国药准字H61021680 | 2ml:20mg | Category A (甲) | XC03CAF056B002010302503 | NHSA |
| 遂成药业股份有限公司 | 国药准字H41021056 | 2ml:20mg | Category A (甲) | XC03CAF056B002010303204 | NHSA |
| 吉林省辉南长龙生化药业股份有限公司 | 国药准字H20249770 | 2ml:20mg | Category A (甲) | XC03CAF056B002010303421 | NHSA |
| 福建南少林药业有限公司 | 国药准字H35020028 | 2ml:20mg | Category A (甲) | XC03CAF056B002010304784 | NHSA |
| 吉林振澳制药有限公司 | 国药准字H20233896 | 2ml:20mg | Category A (甲) | XC03CAF056B002010309876 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20244405 | 2ml:20mg | Category A (甲) | XC03CAF056B002010383033 | NHSA |
| 遂成药业股份有限公司 | 国药准字H41021056 | 2ml:20mg | Category A (甲) | XC03CAF056B002010403204 | NHSA |
| 陕西顿斯制药有限公司 | 国药准字H61021680 | 2ml:20mg | Category A (甲) | XC03CAF056B002010502503 | NHSA |
| 陕西顿斯制药有限公司 | 国药准字H61021680 | 2ml:20mg | Category A (甲) | XC03CAF056B002010602503 | NHSA |
| 上海朝晖药业有限公司 | 国药准字H31021075 | 2ml:20mg | Category A (甲) | XC03CAF056B002020100665 | NHSA |
| 北京京丰制药集团有限公司 | 国药准字H12020527 | 2ml:20mg | Category A (甲) | XC03CAF056B002020100874 | NHSA |
| 湖北天圣药业有限公司 | 国药准字H42020417 | 2ml:20mg | Category A (甲) | XC03CAF056B002020101842 | NHSA |
| 武汉久安药业有限公司 | 国药准字H20249586 | 10ml:100mg | Category A (甲) | XC03CAF056B002020101949 | NHSA |
| 山西国润制药有限公司 | 国药准字H14020650 | 2ml:20mg | Category A (甲) | XC03CAF056B002020102839 | NHSA |
| 吉林省集安益盛药业股份有限公司 | 国药准字H22021500 | 2ml:20mg | Category A (甲) | XC03CAF056B002020103425 | NHSA |
| 山东圣鲁制药有限公司 | 国药准字H37021208 | 2ml:20mg | Category A (甲) | XC03CAF056B002020104207 | NHSA |
| 安徽长江药业有限公司 | 国药准字H34021984 | 2ml:20mg | Category A (甲) | XC03CAF056B002020104451 | NHSA |
| 海鸿恒隆(海南)生物科技有限公司 | 国药准字H20213920 | 2ml:20mg | Category A (甲) | XC03CAF056B002020110144 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20244406 | 10ml:100mg | Category A (甲) | XC03CAF056B002020183033 | NHSA |
| 武汉久安药业有限公司 | 国药准字H20249586 | 10ml:100mg | Category A (甲) | XC03CAF056B002020201949 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20244406 | 10ml:100mg | Category A (甲) | XC03CAF056B002020283033 | NHSA |
| 仁合益康集团有限公司 | 国药准字H20244406 | 10ml:100mg | Category A (甲) | XC03CAF056B002020383033 | NHSA |
| 海南金瑞宝医药科技有限公司 | 国药准字H20233276 | 2ml:20mg | Category A (甲) | XC03CAF056B002010283048 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 6 filings and 6 distinct first applicants.
Generic 5 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 安徽双鹤药业有限责任公司 | CYHS2602123 | Generic | 2026/08/26 | Not stated by source | CDE |
| 江西泰吉立生物制药有限公司 | CYHS2601301 | Generic | 2026/06/04 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2600651 | Generic | 2026/03/12 | Not stated by source | CDE |
| 山东益健药业有限公司 | CYHB2550377 | Supplement | 2025/12/02 | Not stated by source | CDE |
| 亚邦医药股份有限公司 | CYHS2503622 | Generic | 2025/10/11 | Not stated by source | CDE |
| 河南普瑞药业有限公司 | CYHS2503598 | Generic | 2025/10/09 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 安徽双鹤药业有限责任公司 | CYHS2602123 | Generic | 2026/08/26 | Not stated by source | CDE |
| 江西泰吉立生物制药有限公司 | CYHS2601301 | Generic | 2026/06/04 | Not stated by source | CDE |
| 信合援生制药股份有限公司 | CYHS2600651 | Generic | 2026/03/12 | Not stated by source | CDE |
API registrations
Non-component matches: 20 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 呋塞米 | 黄石福尔泰医药科技有限公司 | Y20250000155 | A | Exact ingredient | 2026/07/14 | CDE |
| 呋塞米 | 云鹏医药集团有限公司 | Y20250000026 | A | Exact ingredient | 2026/06/11 | CDE |
| 呋塞米 | 海南卓科制药有限公司 | Y20240001396 | A | Exact ingredient | 2026/06/11 | CDE |
| 呋塞米 | 河北国龙制药有限公司 | Y20240001516 | A | Exact ingredient | 2026/07/21 | CDE |
| 呋塞米 | SRI KRISHNA PHARMACEUTICALS LIMITED UNIT IV | Y20230001118 | A | Exact ingredient | 2026/07/21 | CDE |
| 呋塞米 | 四川省玉鑫药业有限公司 | Y20240000125 | A | Exact ingredient | 2025/07/28 | CDE |
| 呋塞米 | 北京京丰制药（山东）有限公司 | Y20230000311 | A | Exact ingredient | 2026/10/21 | CDE |
| 呋塞米 | 遂成药业股份有限公司 | Y20230000252 | A | Exact ingredient | 2024/06/12 | CDE |
| 呋塞米 | 湖南欧亚药业有限公司 | Y20220000566 | A | Exact ingredient | 2026/04/08 | CDE |
| 呋塞米 | 河南精康制药有限公司 | Y20220000320 | A | Exact ingredient | 2024/09/20 | CDE |
| 呋塞米 | Mangalam Drugs and Organics Ltd. | Y20200000835 | A | Exact ingredient | 2026/10/15 | CDE |
| 呋塞米 | Assia Chemical Industries Ltd. | Y20200001166 | A | Exact ingredient | 2025/05/17 | CDE |
| 呋塞米 | 广州白云山医药集团股份有限公司白云山制药总厂 | Y20219990005 | A | Exact ingredient | — | CDE |
| 呋塞米 | Curia India Private Limited | Y20190009097 | A | Exact ingredient | 2025/06/03 | CDE |
| 呋塞米 | 常州亚邦制药有限公司 | Y20190008722 | A | Exact ingredient | 2025/07/24 | CDE |
| 呋塞米 | 北京太洋药业股份有限公司 | Y20190005487 | A | Exact ingredient | — | CDE |
| 呋塞米 | 东北制药集团股份有限公司 | Y20190003799 | A | Exact ingredient | 2024/04/24 | CDE |
| 呋塞米 | 台山市新宁制药有限公司 | Y20190002797 | A | Exact ingredient | 2026/02/27 | CDE |
| 呋塞米 | 北京京丰制药（山东）有限公司 | Y20190002195 | A | Exact ingredient | 2023/04/23 | CDE |
| 呋塞米 | 辽源市百康药业有限责任公司 | Y20190002139 | A | Exact ingredient | 2026/03/04 | CDE |
| 呋塞米 | Ipca Laboratories Limited | Y20170000088 | A | Exact ingredient | 2024/06/27 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/03Marketing application approved
华夏生生药业（北京）有限公司
CYHS2501124 · 国药准字H20266489
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Site observation date: 2026/11/06
The loaded NHSA codes and chemical-drug catalogue contain no evidence confirming an earlier same-name approval for this company. This does not establish the absence of an earlier approval.
View source · Table row 41 ↗ -
2026/08/26Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Furosemide Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy